SandboxAB: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 61: | Line 61: | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluoroquinolones]]'''''<br>'''''[[Ciprofloxacin]] 500 mg PO bid ×7 days | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluoroquinolones]]'''''<br>'''''[[Ciprofloxacin]] 500 mg PO bid ×7 days<br>[[Levofloxacin]] 750 mg PO q24 × 5 days<br>[[Ofloxacin]] 400 mg Po bid<br>[[Moxifloxacin]] 400 mg PO q24h''''' | ||
|- | |- |
Revision as of 09:20, 17 January 2014
‡Avoid if resistance prevalence is known to exceed 20% or if used for UTI in previous 3 months. ♦Pivmecillinam is available in some European countries, not licensed in US.
|